

## Description

Adis R&D Insight provides international coverage of drugs in research and development. Drugs are monitored through all development phases and information includes: an Adis evaluated rating of therapeutic value, adverse events, pharmacology, pharmacokinetics, pharmacodynamics, pharmacoeconomics, therapeutic trials, and development phases by indication and country.

Data is collected from over 2,300 biomedical journals covering drugs and therapeutics, news services, newsletters, company annual reports, contact with companies, market intelligence, meetings and conferences.

## Date Coverage

1995–present

## Geographic Coverage

International

## Publisher

Adis R&D Insight is provided by Wolters Kluwer Pharma Solutions. Questions concerning file content should be directed to:

Wolters Kluwer Pharma Solutions

Client Services Department  
770 Township Line Road, Suite 300  
Yardley, PA 19067

### Telephone:

+1-877-872-2347 ex 1  
+1-267-757-3421 ex 1

### Fax:

+1-267-757-0652

### E-Mail:

sarah.schweer@wolterskluwer.com

## Subject Coverage

Information reported in **Adis R&D Insight** includes:

- Generic Name, Synonyms, Brand Names
- Developing Companies
- Development Phases by Indication and Country
- Adverse Events, Pharmacology, Pharmacokinetics, Pharmacodynamics, Therapeutic Trials
- Development History
- Adis's own unique Therapeutic Value Rating

Adis R&D Insight profiles are also backed by more than 10,000 evaluated Adis scientific summaries and 63,000 bibliographic references.

## Update Frequency

Weekly

## Document Types

Reports

## Terms & Conditions

Database copyrighted by Adis Data Information BV. Data may not be duplicated in hard copy or machine-readable format without written permission of Adis Data Information BV.

[Dialog Standard Terms & Conditions](#) apply.

## Notes:

Field codes may be used in searches entered on the Basic Search, Advanced Search and Command Line Search pages. The tools available for searching are [Search Fields](#), [Limit Options](#), [Browse Fields](#), [“Narrow Results By” Limiters](#) and [Look Up Citation](#). Each is listed separately below. Some data can be searched using more than one tool.

## SEARCH FIELDS

Field name	Field code	Example	Selectable from Advanced Search form drop-down menu	Available as Limit Option	Available Look up / Browse	Displayed in Document View	Description and Notes
Accession number	AN	an(014136)	No	No	No	Yes	A unique document identification number assigned by the information provider.
All fields (no full text)	ALL	all(potassium and adverse events)	Yes	No	No	Yes	
All fields (plus full text)	–	potassium and adverse events	Yes	No	No	Yes	
CAS <sup>®</sup> Registry number	RN	rn("124750-99-8")	Yes	No	No	Yes	Also searchable using the Substance search field (SUBST).
Classification	CL	cl(antineoplastics)	Yes	Yes	Yes	Yes	Displayed as "Therapeutic class".
Company	COM	com(3m healthcare)	Yes	No	No	Yes	Search includes both the Licensee and the Originator; displayed as "Originator", no display for Licensee.
Country	CN	cn(japan) cn(usa)	No	No	No	Yes	Drug company country; displayed with the Originator and Licensee.
Country of launch/development	CLD	cld(brazil)	Yes	No	No	Yes	Displayed in the "DEVELOPMENT PHASE" section of the text.
Document text	TX	tx(intracellular calcium)	Yes	Yes	No	Yes	
Document title	TI	ti(riluzole)	Yes	No	No	Yes	Drug name.
Document type	DTYPE	dtype(report)	No	No	No	Yes	All documents contain "Report".
Drug synonym	SYN	syn(Ethinylestradiol)	No	No	No	Yes	
Generic name	GN	gn(ezetimibe)	Yes	No	No	No	Also searchable using the Substance search field (SUBST).
Highest phase	HP	hp(preclinical)	Yes	Yes	Yes	Yes	
Indications	IND	ind(acne 60)	Yes	No	No	Yes	

Field name	Field code	Example	Selectable from Advanced Search form drop-down menu	Available as Limit Option	Available Look up / Browse	Displayed in Document View	Description and Notes
Last update date	LUPD	lupd(20111110) lupd(>20111110) lupd(>=20110415) lupd(<20050630) lupd(2010101 - 20110201) lupd(2011-11-10)	No	Yes	No	Yes	
Licensee	LCO	lco(shionogi pharma)	Yes	No	No	No	Also searchable using the Company search field (COM).
Mechanism of action	MEC	mec(11-beta hydroxysteroid dehydrogenase inhibitors)	Yes	Yes	Yes	Yes	Displayed in the "PHARMACOLOGY OVERVIEW" section of the text.
Molecular formula	MF	mf(c24 h21 f2 n o3)	Yes	No	No	Yes	
Originator	DOR	dor("sanofi-aventis")	Yes	No	No	Yes	Also searchable using the Company search field (COM).
Pharmacokinetics	PK	pk(rheumatoid arthritis)	No	No	No	Yes	
Pharmacological action	ACT	act(cyclophilin inhibitors)	No	No	No	Yes	Displayed in the "PHARMACOLOGY OVERVIEW" section of the text.
Pharmacology	PK	pk(neuroprotective effects)	Yes	No	No	Yes	Displayed in the "PHARMACOLOGY OVERVIEW" section of the text.
Phase	PHS	phs(discontinued) phs("phase iii") phs("phase iii" lnk "cervical cancer"))	Yes	Yes	Yes	Yes	Includes the phase, country and indication.
Publication date	PD	pd(20110415) pd(>20110415) pd(>=20110415) pd(<20050630) pd(2010101 - 20110201) pd(2010-10-18)	No	Yes	No	Yes	
Publication title	PUB	pub("adis r&d insight")	No	No	No	Yes	All Publication titles contain "Adis R&D Insight".

Field name	Field code	Example	Selectable from Advanced Search form drop-down menu	Available as Limit Option	Available Look up / Browse	Displayed in Document View	Description and Notes
Publication type	RTYPE	rtype(report)	No	No	No	Yes	All documents contain "Report".
Publication year	YR	yr(2007) yr(2009-2011) yr(2009:2011) yr(>2009) yr(<2009)	No	No	No	Yes	
References	REF	ref("Optimer Pharmaceuticals" Ink "4 Apr 2006")	No	No	No	Yes	
Route of administration	RO	ro(iv)	Yes	No	No	Yes	Also displayed in the "CLINICAL OVERVIEW" section of the text.
Subject	SUB	sub(enzyme inhibitors)	Yes	No	No	Yes	Therapeutic class name; displayed as "Therapeutic class".
Substance	SUBST	subst(pyrrolidinium)	Yes	No	No	Yes	Includes trade name, generic name, and CAS Registry number.
Therapeutic trials	THT	tht(preclinical)	Yes	No	No	No	
Therapy status	TST	tst(preclinical)	Yes	No	No	No	
Trade name	TNS	tns(relistor)	Yes	Yes	No	Yes	Also searchable using the Substance search field (SUBST).
Word count	WC	wc(>2500) wc(<2500)	No	No	No	Yes	

## LIMIT OPTIONS

Limit options are quick and easy ways of searching certain common concepts. Check boxes are available for:

**Full text, Drugs with a tradename, Documents with images**

Short lists of choices are available for:

**Phase, Highest phase, Drug status**

**Date limiters** are available in which you can select single dates or ranges for date of **publication**.

## ***BROWSE FIELDS***

You can browse the contents of certain fields by using Look Up lists. These are particularly useful to validate spellings or the presence of specific data. Terms found in the course of browsing may be selected and automatically added to the Advanced Search form. Look Up lists are available in the fields drop-down and in the search options for:

**Classification code, Mechanism of action**

and in the fields drop-down only for:

**Company, Indication**

## ***“NARROW RESULTS BY” LIMITERS***

When results of a search are presented, the results display is accompanied by a list of “Narrow results by” options shown on the right-hand panel. Click on any of these options and you will see a ranked list showing the most frequently occurring terms in your results. Click on term(s) to include or exclude and apply them to (“narrow”) your search results. “Narrow results by” limiters in Adis R&D Insight include

**Classification, Highest phase, Company, Publication date, Mechanism of action**

## ***LOOK UP CITATION***

If you need to trace a particular bibliographic reference, use the Look Up Citation feature. Find a link to this toward the top left of the Advanced Search page, or in the drop list under Advanced on any search form; click this link and you will go to a form where you can enter any known details of the citation, including document title, author, journal name, volume, issue, page, publication date, ISSN.

### **Contact the Dialog Knowledge Center**

Within North America 1 800 3 DIALOG (1 800 334 2564)

Outside North America 00 800 33 DIALOG (00 800 33 34 2564)

Email: [Customer@dialog.com](mailto:Customer@dialog.com)